Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $779.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 22.49% year-over-year to $779.0 million; the TTM figure through Mar 2026 stood at $779.0 million (down 22.49% YoY), while the FY2025 annual figure was $914.0 million, down 1.08% from the prior year.
• Total Current Liabilities was $779.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $914.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q4 2023 to a low of $779.0 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $992.9 million across 5 years, with a median of $985.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities increased 26.74% in 2022, then fell 27.87% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $1.0 billion in 2022, then grew by 25.71% to $1.3 billion in 2023, then dropped by 27.87% to $924.0 million in 2024, then declined by 1.08% to $914.0 million in 2025, then fell by 14.77% to $779.0 million in 2026.
• The last three Total Current Liabilities figures came in at $779.0 million (Q1 2026), $914.0 million (Q4 2025), and $965.0 million (Q3 2025), per Business Quant data.